Detalhe da pesquisa
1.
Pregnancy, fertility concerns and fertility preservation procedures in a national study of French breast cancer survivors.
Reprod Biomed Online
; 44(6): 1031-1044, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35525718
2.
Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer.
Breast Cancer Res Treat
; 189(2): 377-386, 2021 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-34264439
3.
Prospective Multicenter Study Validate a Prediction Model for Surgery Uptake Among Women with Atypical Breast Lesions.
Ann Surg Oncol
; 28(4): 2138-2145, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-32920723
4.
Nonpalpable breast lesions: impact of a second-opinion review at a breast unit on BI-RADS classification.
Eur Radiol
; 31(8): 5913-5923, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-33462625
5.
6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial.
Lancet
; 393(10191): 2591-2598, 2019 06 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-31178155
6.
Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial.
Breast Cancer Res
; 21(1): 121, 2019 11 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-31727113
7.
Vinorelbine thiotepa in metastatic breast cancer: a large real-life retrospective study.
Acta Oncol
; 62(12): 1961-1966, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37750392
8.
Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet Oncol
; 18(10): 1360-1372, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28800861
9.
18FDG-PET/CT for predicting the outcome in ER+/HER2- breast cancer patients: comparison of clinicopathological parameters and PET image-derived indices including tumor texture analysis.
Breast Cancer Res
; 19(1): 3, 2017 01 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28057031
10.
Correlation between tumour characteristics, SUV measurements, metabolic tumour volume, TLG and textural features assessed with 18F-FDG PET in a large cohort of oestrogen receptor-positive breast cancer patients.
Eur J Nucl Med Mol Imaging
; 44(7): 1145-1154, 2017 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-28188325
11.
Use of iron sucrose and red blood cell transfusions in anaemic cancer patients in France (OncoFer study).
Support Care Cancer
; 25(3): 973-982, 2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-27915456
12.
¹8F-FDG PET/CT in the early prediction of pathological response in aggressive subtypes of breast cancer: review of the literature and recommendations for use in clinical trials.
Eur J Nucl Med Mol Imaging
; 43(5): 983-993, 2016 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-26758726
13.
Anti-Müllerian hormone in breast cancer patients treated with chemotherapy: a retrospective evaluation of subsequent pregnancies.
Reprod Biomed Online
; 32(3): 299-307, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26803206
14.
Letter to the Editor: PET/CT in Locally Advanced Breast Cancer: Time for a Guideline Change?
J Natl Compr Canc Netw
; 19(8): xxx, 2021 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34416711
15.
Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial.
Lancet Oncol
; 16(16): 1700-10, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26596672
16.
Early Metabolic Response to Neoadjuvant Treatment: FDG PET/CT Criteria according to Breast Cancer Subtype.
Radiology
; 277(2): 358-71, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25915099
17.
Do clinical, histological or immunohistochemical primary tumour characteristics translate into different (18)F-FDG PET/CT volumetric and heterogeneity features in stage II/III breast cancer?
Eur J Nucl Med Mol Imaging
; 42(11): 1682-1691, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26140849
18.
Cancer Risk in Women Exposed to Diethylstilbestrol in Utero.
Therapie
; 70(5): 433-41, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26071143
19.
Ovarian reserve in breast cancer: assessment with anti-Müllerian hormone.
Reprod Biomed Online
; 29(5): 573-80, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25246112
20.
6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.
Lancet Oncol
; 14(8): 741-8, 2013 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-23764181